KUALA LUMPUR: Duopharma Biotech Bhd became the first pharmaceutical company in Malaysia to receive halal certification for an oncology product from the Department of Islamic Development Malaysia.
Duopharma Biotech said the product was approved as an adjuvant treatment for postmenopausal women with early breast cancer, as well as a first-line treatment for postmenopausal women with advanced breast cancer.
It is manufactured at the company's highly potent active pharmaceutical ingredients (HAPI) facility in Glenmarie, Shah Alam, near here.
"The product is supplied to government and private healthcare hospitals in Malaysia and has recently been approved for export to Brunei and Singapore," the company said.
Duopharma Biotech group managing director Leonard Ariff Abdul Shatar described the product's halal certification as a milestone for the company, in line with its environmental, social and governance (ESG) commitment, where access to medicine is one of the key focus areas.
"We are making continuous efforts to provide consumers and patients with access to much-needed medicines and therapies, which are safe for use and effective, as well as of high quality, hygienic and halal.
"Our state-of-the-art HAPI facility plays a vital role in the fight against diseases, enabling the company to embrace innovation and technology to serve the needs of patients and expand their access to specialised therapies." -- Bernama